Sign in

slimfourati.bsky.social

@slimfourati.bsky.social
70 followers 46 following 5 posts
PostsRepliesMedia
slimfourati.bsky.social @slimfourati.bsky.social · 03/06/2026
Very pleased to share our latest work published in The Lancet Microbe. This national collaborative effort was made possible by the incredible dynamism, expertise, and commitment of the ANRS-MIE network and participating centers across France. #RSV #Nirsevimab #PublicHealth #Virology #ANRS-MIE
012
slimfourati.bsky.social @slimfourati.bsky.social · 08/05/2026
Le Baloxavir pourrait bien trouver sa place en combinaison (?) avec un inh polymerase pubmed.ncbi.nlm.nih.gov/31680975/ www.sciencedirect.com/science/arti...
pubmed.ncbi.nlm.nih.gov
An Improved Enzyme-Linked Focus Formation Assay Revealed Baloxavir Acid as a Potential Antiviral Therapeutic Against Hantavirus Infection - PubMed
Hantaviruses, etiologic pathogens responsible for two severe human diseases, exist in areas ranging from Eurasia to America and remain global public health concerns. Conventionally, plaque formation a...
110
slimfourati.bsky.social @slimfourati.bsky.social · 21/04/2026
Fantastic Flavivirus meeting ! Great science and great networking
000
slimfourati.bsky.social @slimfourati.bsky.social · 01/03/2026
Happy to share our preprint “ICU patients with influenza during 2025–26 : a French nationwide cohort study”, conducted within the SEVARVIR consortium, supported and funded by ANRS-MIE. Severe H3N2 in 25–26 (subclade K) did not worsen outcomes in ICU patients. www.medrxiv.org/content/10.6...
medrxiv.org
Clinical and virological characteristics of critically ill patients with influenza in France during the 2025/26 season, marked by the emergence of influenza A(H3N2) clade K
Importance: Recent reports have highlighted an intense influenza activity related to the circulation of the influenza A(H3N2) subclade k variant. There is no data available on the impact of the emerge...
000
slimfourati.bsky.social @slimfourati.bsky.social · 28/11/2025
Bonjour Merci. Attention la grippe B Yamagata s’est probablement éteinte chez l’homme depuis quelques années (conséquences des restrictions post-emergence Covid)
000
Reposted by @slimfourati.bsky.social
Eric Topol @erictopol.bsky.social · 22/10/2025
How do mRNA vaccines help fight cancer? A @nature.com paper today tells the story, one with big implications, as reviewed here erictopol.substack.com/p/how-mrna-v...
erictopol.substack.com
How mRNA Vaccines Can Help Fight Cancer
Turning "cold" tumors "hot"
13604223
Reposted by @slimfourati.bsky.social
Eric Topol @erictopol.bsky.social · 27/06/2025
Not just shingles vaccine, but also RSV vaccine reduces the risk of dementia, which highlights the benefit of revving up the immune system in older individuals www.nature.com/articles/s41...
nature.com
Lower risk of dementia with AS01-adjuvanted vaccination against shingles and respiratory syncytial virus infections - npj Vaccines
npj Vaccines - Lower risk of dementia with AS01-adjuvanted vaccination against shingles and respiratory syncytial virus infections
13432148
Reposted by @slimfourati.bsky.social
Edward Nirenberg @enirenberg.bsky.social · 26/06/2025
In some good news- this is an interesting idea. Lencapavirification (yes I made that term up) of flu antivirals: www.science.org/content/arti... Details on the drug here. www.nature.com/articles/s41...
science.org
A single shot of a flu drug could outperform vaccines—and protect for an entire season
One injection of a long-lasting drug showed up to 76% efficacy in a large trial
67119
Reposted by @slimfourati.bsky.social
The Journal of Infectious Diseases @jidjournal.bsky.social · 04/02/2025
Molecular characterization of RSV infections in elderly patients during the 2023/2024 season in the era of nirsevimab introduction ✅ Just Accepted #IDSky
buff.ly
Molecular characterization of RSV infections in elderly patients during the 2023/2024 season in the era of nirsevimab introduction
RSV can cause severe infections in the elderly. Nirsevimab is a novel prophylactic monoclonal antibody, widely used in infants in France during the 2023/2024 season. It may select for resistant RSV variants that, if transmitted in the community, could compromise vaccine efficacy in the elderly.
186